Related Experiment Video
Updated: May 19, 2026
08:14
MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier (MSC) for Lung Cancer Screening
Published on: October 26, 2017
Plasma microRNA profiles for bladder cancer detection.
Liana Adam1, Matthew F Wszolek, Chang-Gong Liu
1Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Urologic Oncology
|August 7, 2012
Summary
Plasma microRNAs show promise as a noninvasive biomarker for bladder cancer (BC) detection. This study identified specific miRNA signatures with high accuracy for diagnosing BC and its stages.
Area of Science:
- Oncology
- Molecular Biology
- Biomarker Discovery
Background:
- Bladder cancer (BC) presents significant morbidity, mortality, and healthcare costs.
- Novel plasma-based biomarkers are needed for improved BC diagnosis and surveillance.
- Plasma microRNAs (miRNAs) are promising but under-investigated biomarkers for BC.
Purpose of the Study:
- To assess the feasibility and effectiveness of using plasma miRNA signatures for BC detection.
- To identify specific miRNA profiles associated with different stages of bladder cancer.
- To evaluate the diagnostic accuracy of plasma miRNA signatures in distinguishing BC from controls.
Main Methods:
- Plasma miRNA was isolated from 20 BC patients and 18 controls.
- miRNA array analysis was performed using Sanger database probes.
- Logistic regression modeling optimized miRNA signatures for classifying BC stages (MIBC, NMIBC) and controls.
Main Results:
- Seventy-nine differentially expressed plasma miRNAs were identified (FDR <0.5).
- Specific miRNAs (e.g., miR-200b, miR-92, miR-33) showed differential expression related to BC presence and stage.
- Logistic regression achieved high diagnostic accuracy: 89% for BC presence/absence, 92% for invasive BC, 100% for MIBC vs. controls, and 79% for three-way classification.
Conclusions:
- Plasma miRNAs offer a potential noninvasive method for BC detection.
- Further research is needed to refine optimal plasma miRNA signatures.
- Future studies should validate these signatures for clinical applications like initial diagnosis and surveillance.
